MARKET

LPCN

LPCN

Lipocine Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8852
+0.0161
+1.85%
Closed 16:00 05/25 EDT
OPEN
0.8700
PREV CLOSE
0.8691
HIGH
0.9056
LOW
0.8600
VOLUME
75.85K
TURNOVER
55.14K
52 WEEK HIGH
1.890
52 WEEK LOW
0.7080
MARKET CAP
78.34M
P/E (TTM)
-102.9302
1D
5D
1M
3M
1Y
5Y
LPCN: OLE Results
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT
Benzinga · 5d ago
Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients
Benzinga · 05/12 14:55
Lipocine Announces LPCN 1144 NASH Open Label Extension Study Results
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology to develop innovative products to treat neuroendocrine and metabolic disorders, announces positive topline results from its
Benzinga · 05/12 12:03
Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Extension Study
MT Newswires · 05/12 10:52
LPCN: First Quarter 2022 Financial and Operational Results
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT
Benzinga · 05/10 19:31
Lipocine GAAP EPS of -$0.04 misses by $0.02
Lipocine press release (NASDAQ:LPCN): Q1 GAAP EPS of -$0.04 misses by $0.02. As of March 31, 2022, the company had $42.0 million of unrestricted cash, cash equivalents and marketable investment
Seekingalpha · 05/09 12:47
BRIEF-Lipocine Announces Financial Results For The First Quarter Ended March 31, 2022
reuters.com · 05/09 12:40
Shareholders in Lipocine (NASDAQ:LPCN) are in the red if they invested five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
Simply Wall St. · 05/04 10:34
More
No Data
Learn about the latest financial forecast of LPCN. Analyze the recent business situations of Lipocine Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LPCN stock price target is 3.625 with a high estimate of 5.50 and a low estimate of 2.500.
High5.50
Average3.625
Low2.500
Current 0.8852
EPS
Actual
Estimate
-0.030.030.080.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 64
Institutional Holdings: 12.28M
% Owned: 13.88%
Shares Outstanding: 88.50M
TypeInstitutionsShares
Increased
13
572.96K
New
9
1.59M
Decreased
9
369.21K
Sold Out
4
491.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mahesh Patel
Chief Accounting Officer/Controller
Krista Fogarty
Vice President
Nachiappan Chidambaram
Lead Director/Independent Director
Stephen Hill
Director
John Higuchi
Independent Director
Jeffrey Fink
Independent Director
Jill Jene
Independent Director
Richard Ono
Independent Director
Spyros Papapetropoulos
No Data
No Data
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The Company has a portfolio of product candidates designed to produce pharmacokinetic (PK) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects and eliminate gastrointestinal interactions that limit bioavailability. The Company's lead product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates includes LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which is in Phase II testing and TLANDO XR, an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.